1368P TALAPRO-1: Talazoparib monotherapy in metastatic castration-resistant prostate cancer (mCRPC) with DNA damage response alterations (DDRm) – Exploration of tumor genetics associated with prolonged benefit

Bono, Johann S. de; Marcos, E. Castro; Laird, Douglas; Fizazi, Karim; Dorff, Tanya B.; Zhao, S.; Oort, Inge M. van; Gasparro, Donatello; Calabrò, Fabio; Pignata, S.; Gergely, Lajos; Barthélémy, P.; Kilari, Deepak; Hopkins, J.F.; Hc, Chen; Healy, Cynthia G.; Chelliserry, Jijumon; Scagliotti, Giorgio V.; Mehra, N.

doi:10.1016/j.annonc.2022.07.1500

Cited by 3 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…TALAPRO-1 examined the benefits of talazoparib treatment in mCRPC patients according to tumor genetics 14 to try and identify the patients that would benefit most from PARPi therapy. Based on these retrospective, exploratory analyses of TALAPRO-1, patients with BRCA2 copy number loss or homozygous alterations and lack of TP53 alterations exhibited prolonged benefits with PARPi therapy.…”

Section: E591mentioning

confidence: 99%

2022 European Society for Medical Oncology: Meeting highlights

Rendon

Hotte

Morgan

et al. 2022

CUAJ

View full text Add to dashboard Cite

Section: E591mentioning

confidence: 99%

2022 European Society for Medical Oncology: Meeting highlights

Rendon

Hotte

Morgan

et al. 2022

CUAJ

View full text Add to dashboard Cite

Metastatic Castration-Resistant Prostate Cancer: Advances in Treatment and Symptom Management

Kulasegaran,

Oliveira

2024

Curr. Treat. Options in Oncol.

View full text Add to dashboard Cite

Opinion statementThe management of metastatic castrate-resistant prostate cancer (mCRPC) has evolved in the past decade due to substantial advances in understanding the genomic landscape and biology underpinning this form of prostate cancer. The implementation of various therapeutic agents has improved overall survival but despite the promising advances in therapeutic options, mCRPC remains incurable. The focus of treatment should be not only to improve survival but also to preserve the patient’s quality of life (QoL) and ameliorate cancer-related symptoms such as pain. The choice and sequence of therapy for mCRPC patients are complex and influenced by various factors, such as side effects, disease burden, treatment history, comorbidities, patient preference and, more recently, the presence of actionable genomic alterations or biomarkers. Docetaxel is the first-line treatment for chemo-naïve patients with good performance status and those who have yet to progress on docetaxel in the castration-sensitive setting. Novel androgen agents (NHAs), such as abiraterone and enzalutamide, are effective treatment options that are utilized as second-line options. These medications can be considered upfront in frail patients or patients who are NHA naïve. Current guidelines recommend genetic testing in mCRPC for mutations in DNA repair deficiency genes to inform treatment decisions, as for example in breast cancer gene mutation testing. Other potential biomarkers being investigated include phosphatase and tensin homologues and homologous recombination repair genes. Despite a growing number of studies incorporating biomarkers in their trial designs, to date, only olaparib in the PROFOUND study and lutetium-177 in the VISION trial have improved survival. This is an unmet need, and future trials should focus on biomarker-guided treatment strategies. The advent of novel noncytotoxic agents has enhanced targeted drug delivery and improved treatment responses with favourable toxicity profiling. Trials should continue to incorporate and report health-related QoL scores and functional assessments into their trial designs.

show abstract

Therapeutic implications of homologous repair deficiency testing in patients with prostate cancer (Part 2 of 2)

Serritella,

Taylor,

Haffner

et al. 2024

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

Background/Objectives Unfortunately, not all metastatic castration-resistant prostate cancer (mCRPC) patients receive available life-prolonging systemic therapies, emphasizing the need to optimize mCRPC treatment selections. Better guidelines are necessary to determine genetic testing for prostate cancer. Subjects/Methods In this two-part expert opinion-based guide, we provide an expert consensus opinion on the utilization of germline and somatic testing to detect HRR alterations in patients with mCRPC. This guide was developed by a multidisciplinary expert panel that convened in 2023-2024, including representatives from medical oncology, urology, radiation oncology, pathology, medical genomics, and basic science. Results/Conclusions In this second part, we highlight how genetic testing can lead to improved, life-prolonging mCRPC therapeutic strategies based on a review of the recent phase III trials and subsequent regulatory approvals for PARP inhibitors in mCRPC.

show abstract

1368P TALAPRO-1: Talazoparib monotherapy in metastatic castration-resistant prostate cancer (mCRPC) with DNA damage response alterations (DDRm) – Exploration of tumor genetics associated with prolonged benefit

Cited by 3 publications

References 0 publications

2022 European Society for Medical Oncology: Meeting highlights

2022 European Society for Medical Oncology: Meeting highlights

Metastatic Castration-Resistant Prostate Cancer: Advances in Treatment and Symptom Management

Therapeutic implications of homologous repair deficiency testing in patients with prostate cancer (Part 2 of 2)

Contact Info

Product

Resources

About